Saturday |
2:00 pm - 5:00 pm | Arrival and Check-in |
3:30 pm - 3:45 pm | Introductory Comments by GRC Site Staff / Welcome by the GRS Conference Chair |
3:45 pm - 4:30 pm | Keynote Session: Career Development for Early Career Researchers |
| Discussion Leader: Matthew Sikora (University of Pittsburgh, USA) |
3:45 pm - 4:20 pm | Robert Clarke (Georgetown University, USA) "Career Development for Early Career Researchers" |
4:20 pm - 4:30 pm | Discussion |
4:30 pm - 6:00 pm | Poster Session |
6:00 pm | Dinner |
7:30 pm - 9:30 pm | Tumor Biology of Hormone-Dependent Cancers |
| Discussion Leaders: Daniel Frigo (University of Houston, USA) and Ayesha Khan (University of Houston, USA) |
7:30 pm - 7:45 pm | Rajdeep Das (Dame Roma Mitchell Cancer Research Laboratories, Australia) "MicroRNA-194 Is Elevated in Advanced Prostate Cancer and Enhances Metastatic Phenotypes by Targeting SOCS2" |
7:45 pm - 7:50 pm | Discussion |
7:50 pm - 8:05 pm | Alicia Blessing (University of Houston, USA) "Identification of a Novel Coregulator, SH3YL1, that Interacts with the Androgen Receptor N-Terminus" |
8:05 pm - 8:10 pm | Discussion |
8:10 pm - 8:25 pm | Oscar Vidal (National Cancer Institute, NIH, USA) "A Novel Tumor Suppressive Role for the Dopamine Receptor DRD1 in Lung Cancer" |
8:25 pm - 8:30 pm | Discussion |
8:30 pm - 8:45 pm | Valerie Barton (University of Colorado Denver Anschutz Medical Campus, USA) "Androgen Receptor (AR) Supports a Tumor Initiating Population in AR+ Triple-Negative Breast Cancer" |
8:45 pm - 8:50 pm | Discussion |
8:50 pm - 9:05 pm | Ryan Bourgo (University of Chicago, USA) "Capture of Associated Targets on Chromatin (CATCH) Identifies the Presence of eRNAs at Transcriptional Enhancers" |
9:05 pm - 9:10 pm | Discussion |
9:10 pm - 9:25 pm | Laura Baker (Garvan Institute of Medical Research, Australia) "Single-Cell Analysis of Breast Cancer Molecular Subtypes Reveals Clinically Relevant Heterogeneity" |
9:25 pm - 9:30 pm | Discussion |
Sunday |
7:30 am - 8:30 am | Breakfast |
9:00 am - 11:00 am | Endocrine
Therapy and Novel Targets |
| Discussion Leaders: Naomi Laing (AstraZeneca R&D Boston, USA) and Matthew Schiewer (Thomas Jefferson University, USA) |
9:00 am - 9:15 am | Daniel Tamae (University of Pennsylvania, USA) "The DHEA-S Depot May Feed Intratumoral Androgen Biosynthesis via AKR1C3 and Drive Resistance to P450c17 Inhibitors in Castration-Resistant Prostate Cancer" |
9:15 am - 9:20 am | Discussion |
9:20 am - 9:35 am | Yinghui Zhang (Leiden University, The Netherlands) "PAK2/PIX Survival Components Play a Regulatory Role in IGF-1 Receptor-Mediated Antiestrogen Resistance" |
9:35 am - 9:40 am | Discussion |
9:40 am - 9:55 am | Courtney Andersen (University of Pittsburgh, USA) "Identifying Predictive Biomarkers of Endocrine Response in High-Grade Serous Ovarian Cancer" |
9:55 am - 10:00 am | Discussion |
10:00 am - 10:15 am | Brendon Ladd (AstraZeneca, USA) "Effective Combination Therapies in Endocrine Resistant Breast Cancers Harboring an ER Mutation" |
10:15 am - 10:20 am | Discussion |
10:20 am - 10:35 am | Flavia Marialucia Fioretti (Imperial College London, United Kingdom) "Optimization of an Engineered Microrepressor for the Treatment of Castration-Resistant Prostate Cancer" |
10:35 am - 10:40 am | Discussion |
10:40 am - 10:55 am | Sachi Horibata (Cornell University, USA) "Role of Peptidylarginine Deiminase Enzyme 2 in Breast Cancer Progression" |
10:55 am - 11:00 am | Discussion |
11:00 am - 12:30 pm | Poster Session |
| Coffee will be served in the poster area from 11:00 am - 11:30 am |
12:30 pm | Lunch |
1:30 pm - 2:30 pm | Mentorship Component: Career Development Panel Discussion |
| Discussion Leader: Renée de Leeuw (Thomas Jefferson University, USA) |
1:30 pm - 1:35 pm | Daniel Frigo (University of Houston, USA) "Academic Tenure-Track Faculty" |
1:35 pm - 1:45 pm | Discussion |
1:45 pm - 1:50 pm | Remy Brim (Legislative Assistant, USA) "Federal Government and Science Policy" |
1:50 pm - 2:00 pm | Discussion |
2:00 pm - 2:05 pm | Devin Rosenthal (Rho Inc., USA) "Contract Research Organizations" |
2:05 pm - 2:15 pm | Discussion |
2:15 pm - 2:20 pm | Naomi Laing (AstraZeneca R&D Boston, USA) "Pharmaceutical Industry" |
2:20 pm - 2:30 pm | Discussion |
2:30 pm - 3:00 pm | Evaluation Period |
| Fill in GRS Evaluation Forms |
3:00 pm | Seminar Concludes |